- Open
- 1675.00
- High
- 1730.00
- Low
- 1615.00
- Close
- 1615.00
- Change
- -75.00 (-4.48%)
- Volume
- 161
⌘K
| 24 Jun 2026 | 16:10:00 | Director Dealing |
| 18 May 2026 | 08:45:00 | Holding(s) in Company |
| 28 Apr 2026 | 15:45:00 | Director Dealing |
| 20 Apr 2026 | 11:54:25 | Share Options Awarded |
| 13 Apr 2026 |
| 27 Nov 2025 | Annual Report and Accounts (to 2025-06-30) | |
| 10 Dec 2024 | Annual Report and Accounts (to 2024-06-30) | |
| 9 Dec 2023 | Annual Report and Accounts (to 2023-06-30) |
Bioventix produces and provides highly effective sheep monoclonal antibodies (SMAs) that are utilized in diagnostic applications, particularly in clinical blood testing.
| 24 Jun 2026 | 16:10:00 | Director Dealing |
| 18 May 2026 | 08:45:00 | Holding(s) in Company |
| 28 Apr 2026 | 15:45:00 | Director Dealing |
| 20 Apr 2026 | 11:54:25 | Share Options Awarded |
| 13 Apr 2026 |
| 27 Nov 2025 | Annual Report and Accounts (to 2025-06-30) | |
| 10 Dec 2024 | Annual Report and Accounts (to 2024-06-30) | |
| 9 Dec 2023 | Annual Report and Accounts (to 2023-06-30) |
Bioventix produces and provides highly effective sheep monoclonal antibodies (SMAs) that are utilized in diagnostic applications, particularly in clinical blood testing.
| 07:00:07 |
| Director Dealing |
| 07:00:07 |
| Director Dealing |
